These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 11954869)

  • 1. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.
    Naumann M; Yakovleff A; Durif F;
    J Neurol; 2002 Jan; 249(1):57-63. PubMed ID: 11954869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin type B for cervical dystonia.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
    Pappert EJ; Germanson T;
    Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
    Ranoux D; Gury C; Fondarai J; Mas JL; Zuber M
    J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):459-62. PubMed ID: 11909903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
    Rystedt A; Zetterberg L; Burman J; Nyholm D; Johansson A
    Clin Neuropharmacol; 2015; 38(5):170-6. PubMed ID: 26366966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.
    Figgitt DP; Noble S
    Drugs; 2002; 62(4):705-22. PubMed ID: 11893235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.
    Quagliato EM; Carelli EF; Viana MA
    Clin Neuropharmacol; 2010; 33(1):22-6. PubMed ID: 19959960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial.
    Poewe W; Burbaud P; Castelnovo G; Jost WH; Ceballos-Baumann AO; Banach M; Potulska-Chromik A; Ferreira JJ; Bihari K; Ehler E; Bares M; Dzyak LA; Belova AN; Pham E; Liu WJ; Picaut P
    Mov Disord; 2016 Nov; 31(11):1649-1657. PubMed ID: 27653448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin type B for cervical dystonia.
    Marques RE; Duarte GS; Rodrigues FB; Castelão M; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD004315. PubMed ID: 27176573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
    Duarte GS; Castelão M; Rodrigues FB; Marques RE; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD004314. PubMed ID: 27782297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
    Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
    Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals.
    Sloop RR; Cole D; Patel MC
    Mov Disord; 2001 Jan; 16(1):100-5. PubMed ID: 11215566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study.
    Laubis-Herrmann U; Fries K; Topka H
    Eur Neurol; 2002; 47(4):214-21. PubMed ID: 12037435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
    Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
    Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.
    Lew MF; Brashear A; Factor S
    Neurology; 2000; 55(12 Suppl 5):S29-35. PubMed ID: 11188982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.
    Jankovic J; Vuong KD; Ahsan J
    Neurology; 2003 Apr; 60(7):1186-8. PubMed ID: 12682332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.